Rafferty Asset Management Trims Stake in AbbVie

The investment firm reduced its holdings in the pharmaceutical company by 1.2% in the third quarter.

Mar. 3, 2026 at 7:39am

Got story updates? Submit your updates here. ›

Rafferty Asset Management LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 234,130 shares of the company's stock at the end of the quarter, valued at $54,210,000.

Why it matters

This transaction provides insight into the investment decisions of Rafferty Asset Management, a prominent institutional investor. Changes in major shareholders' positions can signal shifts in market sentiment or expectations around a company's performance.

The details

Rafferty Asset Management sold 2,784 shares of AbbVie during the third quarter. The firm now holds 234,130 shares of the pharmaceutical company, worth approximately $54.2 million. This represents a 1.2% reduction in Rafferty's stake in AbbVie.

  • Rafferty Asset Management reduced its AbbVie holdings in the third quarter of 2026.

The players

Rafferty Asset Management LLC

An investment management firm that reduced its stake in AbbVie Inc. during the third quarter of 2026.

AbbVie Inc.

A global biopharmaceutical company focused on developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the ongoing shifts in institutional investors' portfolios and the need to closely monitor changes in major shareholders' positions, as they can provide valuable insights into market sentiment and expectations around a company's future performance.